Pure Maxx

KLOW

GLOW with KPV added — the inflammation-resolution arm.

Skin & dermal · 6 min read · updated 13 Aug 2026

Research use only. The ranges below are what published studies and community protocols report. They are reference material for laboratory research, not medical advice or a recommendation for human or veterinary use.

The compound

KLOW

View
Type
Regenerative & Anti-Inflammatory Blend
CAS
N/A (Blend)
Formula
N/A (Blend)
Mass
N/A (Blend)

At a glance

Class
Four-peptide repair and anti-inflammatory blend
Composition
BPC-157 + TB-500 + GHK-Cu + KPV
Total per vial
80 mg
Typical ratio
10 : 10 : 50 : 10 by mass
Vial size stocked
80 mg

KLOW is the GLOW blend with 10 mg of KPV added. The rationale is straightforward: GLOW covers vascular supply, cell migration and matrix synthesis, but it has no dedicated arm for damping the inflammatory signalling that accompanies injury. KPV inhibits NF-κB intracellularly, which is exactly that missing arm.

This makes KLOW the more complete blend on paper, and the one that suits research questions where inflammation is a central feature rather than a background process. The trade-off is that it compounds the fundamental problem of blends: four fixed ratios instead of three, and even less ability to tune any one component.

Read the BPC-157, TB-500, GHK-Cu and KPV articles first — this piece covers only what the combination adds.

The blend arithmetic

At the 10:10:50:10 ratio the vial totals 80 mg. Divide a blend dose by 8 to get the BPC-157, TB-500 and KPV amounts individually; multiply by 5 for the GHK-Cu amount.

Worked example: a 2 mg blend dose delivers 0.25 mg BPC-157, 0.25 mg TB-500, 1.25 mg GHK-Cu and 0.25 mg KPV. Every component lands inside its own commonly reported range — which is why 2 mg is the dose most reported protocols converge on.

Confirm the ratio on the vial you actually hold. Blend compositions are not standardised across suppliers, and a different ratio changes every number above.

When KLOW rather than GLOW

  • Inflammation is part of the research question rather than incidental — the KPV arm is the entire reason the blend exists.
  • Gastrointestinal models, where BPC-157 and KPV both have a specific literature and act through different mechanisms.
  • Dermal inflammation, where KPV's small size supports tissue penetration and GHK-Cu supplies the matrix arm.
  • If none of those apply, GLOW carries less material for the same repair arms.

Storage

  • Lyophilised: 2–8 °C, or −20 °C for extended storage, protected from light.
  • Reconstituted: 2–8 °C, used within about 28 days. Never freeze.

Cautions

  • All cautions from the four component articles apply in full.
  • NF-κB suppression from the KPV arm sits alongside the angiogenic arms — a combination that has no safety characterisation as a combination.
  • TB-500 is on the WADA prohibited list, and so is this blend.
  • Attribution is impossible with four components. If something happens, the blend cannot tell you which arm did it.

References & credit

  1. 1See the individual articles — BPC-157, TB-500, GHK-Cu and KPV each carry their own reference list.

This article was written in-house. Where a dose range reflects community practice rather than a published trial, the community references we consulted are credited above and the article says which is which.

In the catalogueKLOW

Keep reading

8 minGHK-CuA copper-carrying tripeptide that behaves more like a transcriptional signal than a nutrient.7 minGlutathioneThe cell's principal thiol antioxidant — and the reason route of administration decides everything.6 minGLOWBPC-157 + TB-500 + GHK-Cu in one vial — and the arithmetic that comes with it.16 minHarm mitigationThe failure modes that repeat across every compound here, and what actually reduces them.
All protocol guides
    KLOW — GLOW with KPV added — the inflammation-resolution arm.